| Standard dose eligible that received low dose Dabigatran (n = 1013) | Standard dose eligible that received standard dose Dabigatran (n = 5621) | P value | Before Matching Standardized Difference | After Matching (N = 1001 vs 1001) Standardized Difference |
---|---|---|---|---|---|
Year |  |  | < 0.001 |  |  |
 2010–12 | 50.0% | 55.7% |  | 0.116 | 0.198 |
 2013 | 18.6% | 13.6% |  | 0.137 | 0.174 |
 2014 | 11.6% | 11.4% |  | 0.008 | 0.032 |
 2015 | 10.9% | 10.1% |  | 0.026 | 0.047 |
 2016–17 | 9.0% | 9.3% |  | 0.009 | 0.040 |
Region | Â | Â | 0.8 | Â | Â |
 Midwest | 12.3% | 12.9% |  | 0.017 | 0.024 |
 Northeast | 1.7% | 1.5% |  | 0.018 | 0.016 |
 South | 73.7% | 74.3% |  | 0.012 | 0.009 |
 West | 12.2% | 11.4% |  | 0.027 | 0.006 |
Age Category |  |  | < 0.001 |  |  |
 65–69 | 6.7% | 18.7% |  | 0.365 | 0 |
 70 to 74 | 12.5% | 27.3% |  | 0.3755 | 0 |
 75 to 79 | 19.0% | 24.9% |  | 0.143 | 0 |
 80 to 84 | 26.4% | 17.9% |  | 0.206 | 0 |
 85 to 89 | 18.5% | 6.9% |  | 0.351 | 0 |
 90 or over | 17.0% | 4.4% |  | 0.415 | 0 |
Sex |  |  | < 0.001 |  |  |
 Female | 55.6% | 46.8% |  | 0.176 | 0 |
 Male | 44.4% | 53.2% |  |  |  |
Race Category |  |  | < 0.001 |  |  |
 White | 84.0% | 87.9% |  | 0.113 | 0 |
 Black | 10.1% | 6.6% |  | 0.126 | 0 |
 Hispanic | 2.5% | 1.6% |  | 0.059 | 0 |
 Asian | 1.2% | 0.6% |  | 0.066 | 0 |
 Other | 2.3% | 3.3% |  | 0.060 | 0 |
 Smoker | 15.0% | 16.8% | 0.15 | 0.049 | 0.037 |
Weight Category (based on ICD-9/ ICD-10 codes for BMI) | Â | Â | 0.003 | Â | Â |
 Under Weight | 1.1% | 0.6% |  | 0.057 | 0.031 |
 Healthy or Overweight | 10.8% | 8.3% |  | 0.082 | 0.013 |
 Obese or Severe Obese | 20.0% | 23.4% |  | 0.084 | 0.054 |
 Others | 68.1% | 67.6% |  | 0.010 | 0.061 |
Comorbid Conditions | |||||
 Prior Stroke | 26.9% | 23.9% | 0.04 | 0.067 | 0.011 |
 Prior Major Bleeding | 25.8% | 23.9% | 0.2 | 0.044 | 0.042 |
 Diabetes | 48.9% | 48.0% | 0.6 | 0.018 | 0.066 |
 Prior AMI | 6.9% | 5.0% | 0.01 | 0.082 | 0.103 |
 Liver Disease | 3.6% | 2.5% | 0.07 | 0.059 | 0.126 |
 Heart Failure | 45.0% | 29.7% | < 0.001 | 0.320 | 0.274 |
 Hypertension | 95.1% | 93.0% | 0.01 | 0.089 | 0.088 |
 Ischemic Cardiomyopathy | 53.4% | 46.4% | < 0.001 | 0.140 | 0.110 |
 Pulmonary Circulatory Disease | 15.6% | 11.0% | < 0.001 | 0.135 | 0.083 |
 COPD | 35.7% | 31.0% | 0.003 | 0.1 | 0.115 |
 Blood Transfusion | 3.2% | 2.4% | 0.18 | 0.044 | 0 |
 Revascularization | 16.8% | 14.5% | 0.05 | 0.063 | 0.075 |
 Implantable cardiac device | 15.5% | 13.1% | 0.04 | 0.068 | 0.011 |
 Valve Disease | 44.1% | 40.0% | 0.015 | 0.083 | 0.024 |
Concurrent Drugs (+/− 90 days of initiating DOAC) | |||||
 SSRI/SNRI | 34.0% | 30.0% | 0.01 | 0.085 | 0.126 |
 Strong and moderate p-gp inhibitors | 7.3% | 12.9% | < 0.001 | 0.188 | 0.135 |
 Warfarin | 19.9% | 24.0% | 0.004 | 0.099 | 0.237 |
 Strong p-gp and cyp3a4 dual inhibitors | 17.0% | 18.2% | 0.3 | 0.0325 | 0.032 |
 ACE inhibitors | 68.4% | 67.2% | 0.45 | 0.0257 | 0.081 |
 Angiotensin receptor blockers | 38.6% | 38.1% | 0.8 | 0.0094 | 0.010 |
 Beta blockers | 90.7% | 88.4% | 0.03 | 0.0759 | 0.108 |
 Calcium channel blockers | 65.5% | 63.2% | 0.15 | 0.0488 | 0.040 |
 Digoxin | 32.1% | 28.7% | 0.03 | 0.0741 | 0.002 |
 Proton pump inhibitors | 58.7% | 55.2% | 0.04 | 0.0707 | 0.008 |
 NSAIDs | 48.3% | 50.4% | 0.2 | 0.0433 | 0.04 |
 Antiplatelets | 30.5% | 25.7% | 0.0015 | 0.1064 | 0.093 |
 Insulin | 14.5% | 12.1% | 0.03 | 0.072 | 0.137 |
 Statins | 79.1% | 78.7% | 0.8 | 0.009 | 0.079 |
Renal Disease |  |  | < 0.001 |  |  |
 None or Mild | 33.6% | 57.2% |  | 0.489 | 0.255 |
 Moderate (GFR 30–60 ml/min/1.73 m2) | 66.4% | 42.8% |  |  |  |
Severe (GFR < 30 ml/min/1.73 m2) | 0.0% | 0.0% |  |  |  |